Write in a clean editor, then format for ACS Medicinal Chemistry Letters in one click — DocuGuru applies the official American Chemical Society template with superscript references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
ACS Medicinal Chemistry Letters is a peer-reviewed journal published by American Chemical Society, covering Computational Drug Discovery Methods, Receptor Mechanisms and Signaling, Protein Degradation and Inhibitors. Over its lifetime it has published 5,494 papers, which have received 106,737 citations.
| Publisher | American Chemical Society |
|---|---|
| Reference style | Superscript numbered (ACS) Superscript — small raised numerals in the text (1) Smith, A.; Jones, B.; Lee, C. A Representative Article Title. ACS Medicinal Chemistry Letters 2023, 12, 45–58.
Formats any DOI in ACS Medicinal Chemistry Letters style. No sign-up. |
| Publishes research in | Computational Drug Discovery Methods Receptor Mechanisms and Signaling Protein Degradation and Inhibitors Peptidase Inhibition and Analysis Chemical Synthesis and Analysis |
| ISSN | 1948-5875 |
| Citation impact (2-yr) | 1.95 |
| h-index | 109 |
| i10-index | 2,686 |
| Top institutions publishing here | Merck & Co., Inc., Rahway, NJ, USA (United States) |
| Journal website | pubs.acs.org |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the production of d-2-hydroxyglutarate (2-HG), an oncometabolite. Elevated 2-HG levels are implicated in epigenetic alterations and impaired cellular differentiation. IDH1 mutations have been…
Large arrays of hypothesis-driven, rationally designed experiments are powerful tools for solving complex chemical problems. Conceptual and practical aspects of chemical high-throughput experimentation are discussed. A case study in the application of high-throughput experimentation to a key synthetic step in a drug discovery program and subsequent optimization for the first large scale synthesis of a…
The p53 tumor suppressor is a potent transcription factor that plays a key role in the regulation of cellular responses to stress. It is controlled by its negative regulator MDM2, which binds directly to p53 and inhibits its transcriptional activity. MDM2 also targets p53 for degradation by the proteasome. Many tumors produce high levels of…
The histone H3-lysine 27 (H3K27) methyltransferase EZH2 plays a critical role in regulating gene expression, and its aberrant activity is linked to the onset and progression of cancer. As part of a drug discovery program targeting EZH2, we have identified highly potent, selective, SAM-competitive, and cell-active EZH2 inhibitors, including GSK926 (3) and GSK343 (6). These…
Phosphoinositide 3-kinase α (PI3Kα) is a critical regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers. The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative…
